Evidence
Life Sci. 2024 Jan 17:122431. doi: 10.1016/j.lfs.2024.122431. Online ahead of print.
ABSTRACT
Liver disease has become one of the main causes of health issue worldwide. Sirtuin (Sirt) 2 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, and is expressed in multiple organs including liver, which plays important and complex roles by interacting with various substrates. Physiologically, Sirt2 can improve metabolic homeostasis. Pathologically, Sirt2 can alleviate inflammation, endoplasmic reticulum (ER) stress, promote liver regeneration, maintain iron homeostasis, aggravate fibrogenesis and regulate oxidative stress in liver. In liver diseases, Sirt2 can mitigate fatty liver disease (FLD) including non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), but aggravate hepatitis B (HBV) and liver ischemia-reperfusion injury (LIRI). The role of Sirt2 in liver cancer and aging-related liver diseases, however, has not been fully elucidated. In this review, these biological processes regulated by Sirt2 in liver are summarized, which aims to update the function of Sirt2 in liver and to explore the potential role of Sirt2 as a therapeutic target for liver diseases.
PMID:38242495 | DOI:10.1016/j.lfs.2024.122431
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Emerging roles of RNA-binding proteins in fatty liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- The gut-liver axis in fatty liver disease: role played by natural products
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Inflammatory liver diseases and susceptibility to sepsis
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Role of prostaglandin E2 and its receptors in chronic liver disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Role of lactate and lactate metabolism in liver diseases (Review)
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- The double roles of T cell-mediated immune response in the progression of MASLD
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Spatial genomics: mapping human steatotic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Fucoidan from Apostichopus japonicus ameliorates alcoholic liver disease by regulating gut-liver axis homeostasis
- FGL1 and FGL2: emerging regulators of liver health and disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- New nomenclature for fatty liver disease
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
- Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Interleukins in liver disease treatment
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
- Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
- NcRNA Regulated Pyroptosis in Liver Diseases and Traditional Chinese Medicine Intervention: A Narrative Review
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Evidence Blueprint
The role of Sirtuin 2 in liver – An extensive and complex biological process
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The role of Sirtuin 2 in liver – An extensive and complex biological process
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT/NAD+/SIRT1 axis
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Emerging roles of RNA-binding proteins in fatty liver disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Hormone action and liver disease, a complex interplay
- Nicotinamide N-methyltransferase and liver diseases
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Liver sinusoidal endothelial transcription factors in metabolic homeostasis and disease
- Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease
- Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury
- The gut-liver axis in fatty liver disease: role played by natural products
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Inflammatory liver diseases and susceptibility to sepsis
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Puerarin protects the fatty liver from ischemia-reperfusion injury by regulating the PI3K/AKT signaling pathway
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Fatty liver disease's renaming impacts on drug clinical trials
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Corrected and republished from: Metabolic associated liver disease
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Role of lactate and lactate metabolism in liver diseases (Review)
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Metabolic dysfunction: The silenced connection with fatty liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Alcoholic liver disease - 2023
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities